RxDoctor Payments Data

Anthony Farah, MD

Ophthalmology · Williamsburg, VANPI 1659692960

Payments from drug & device makers

$8,323in general payments, 2019–2025

Across 123 payments — averaging $67.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$5K
  • Alcon$784
  • Aerie Pharmaceuticals, Inc.$273
  • Ocular Therapeutix, Inc.$261
  • Rxsight Inc$205
  • AbbVie$193
  • plus $1K from 19 others

What the payments were for

  • Consulting fees$4,50054%
  • Speaking & faculty fees$320%
  • Food & beverage$3,79146%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,323 in reported general payments places this provider in the 85th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$875,478
Medicare patients
1,889
Services billed
6,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine56$73,799
LumiganBimatoprost114$62,981
RhopressaNetarsudil Mesylate46$23,997
Cyclosporine32$23,200
CombiganBrimonidine Tartrate/Timolol52$18,030
Brimonidine Tartrate131$8,287
Latanoprost808$7,934
Prednisolone Acetate181$7,672
CequaCyclosporine11$7,517
ProlensaBromfenac Sodium20$6,896
RocklatanNetarsudil Mesylat/Latanoprost19$6,755
SimbrinzaBrinzolamide/Brimonidine Tart27$6,345
Timolol Maleate129$6,285
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat325$4,963
Brinzolamide20$3,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$193$154,810222 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$273$30,75265 claims
Sun Pharmaceutical Industries Inc.Cequa$164$7,51711 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$51$6,89620 claims
AlconSimbrinza$784$6,34527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Williamsburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →